You are here: Industry Insights > Pfizer

News List

ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever' fiercepharma
June 05, 2019
With ASCO nearing its official close, it's time to round up our favorite quotes from the weekend—a process that's become somewhat of a tradition for us over the last couple of years. Read on to see the most colorful things pharma executives had to say abo
Pfizer announces top-line results from Phase 3 Trial of LYRICA® (pregabalin) in primary generalized tonic-clonic seizures worldpharmanews
May 29, 2019
Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint
Pfizer acquires Therachon to broaden its rare disease pipeline pharmaceutical-technology
May 23, 2019
Pfizer has entered into a definitive agreement to acquire all shares of Therachon, a private clinical-stage biotechnology company focused on rare diseases with pipeline assets in achondroplasia and short bowel syndrome therapies.
Merck’s threat to Pfizer’s lucrative prevnar brand gains ground with positive Phase II results pharmaceutical-technology
May 23, 2019
US drug company Merck and Co Inc. released Phase II trial results on 8 May for its investigational 15-valent conjugate pneumococcal vaccine, V114, which showed overall non-inferiority to ...
Pfizer’s Fragmin approved by the FDA for paediatric patients pharmaceutical-technology
May 22, 2019
The US Food and Drug Administration (FDA) has approved the use of Pfizer’s anticoagulant medicine Fragmin (dalteparin sodium) to minimise the recurrence of symptomatic venous thromboembolism (VTE) in paediatric patients aged one month and above.
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis drugs
May 20, 2019
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis.
Pfizer's abrocitinib smashes primary and secondary endpoints at Phase 3 in atopic dermatitis pharmafile
May 17, 2019
Pfizer has lifted the curtain on new Phase 3 data for its Janus kinase 1 (JAK1) inhibitor abrocitinib, revealing that the therapy met all of its co-primary and secondary endpoints in the treatment of moderate to severe atopic dermatitis (AD) in patients a
Pfizer & Merck's Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer pharmafile
May 16, 2019
The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC).
Pfizer's Vyndaqel, Vyndamax win US nod for rare disease pharmatimes
May 09, 2019
Pfizer's Vyndaqel, Vyndamax win US nod for rare disease.
Pfizer to buy Therachon for $340 million upfront, gaining experimental drug for achondroplasia firstwordpharma
May 09, 2019
Pfizer said Wednesday that it entered into a definitive agreement to acquire all of the shares of Therachon for $340 million upfront, with a further $470 million in milestone payments linked to ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page